Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

NCT07094113 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT07094113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07094113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Recruiting
Start date
July 31, 2025
Completion date
April 20, 2031
Enrollment
434 (estimated)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

kras altered advanced or metastatic solid tumors